Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats (Q44216175)

30 November 2017

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats (English)

1 reference

30 November 2017

0 references

Stefan Carlsson

1

1 reference

PubMed ID

12431484

30 November 2017

Margareta Elg

series ordinal

2

1 reference

PubMed ID

12431484

30 November 2017

Christer Mattsson

series ordinal

3

1 reference

30 November 2017

1 August 2002

1 reference

30 November 2017

1 reference

30 November 2017

107

1 reference

30 November 2017

3-4

1 reference

30 November 2017

163-168

1 reference

Prevention of venous thromboembolism

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

1 reference

7 January 2021

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Kinetics of the inhibition of thrombin by hirudin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900257-8

7 January 2021

10.1016/S0049-3848(02)00257-8

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12431484